Interim report
Page 1
CAP Q2 21 QUARTERLY REPORT DIGNITANA Clinically superior scalp cooling CAUTION DeltaC Or US treatment growth drives 23 percent increase in net revenue UGUST 19 2021 Will
Loading workspace
CAP Q2 21 QUARTERLY REPORT DIGNITANA Clinically superior scalp cooling CAUTION DeltaC Or US treatment growth drives 23 percent increase in net revenue UGUST 19 2021 Will
Your watchlist and earnings event details are available after you sign in.